Cuervo Guillermo, Hernández-Meneses Marta, de Alarcón Arístides, Luque-Marquez Rafael, Alonso-Socas María M, López-Lirola Ana, González-Ramallo Víctor, Goikoetxea-Agirre Ane J, Nicolás David, Goenaga Miguel A, Merino Esperanza, Escrihuela-Vidal Francesc, Martín-Dávila Pilar, Loeches Belén, Boix-Palop Lucía, Gasch Oriol, Camprecios Marta, Hernández-Torres Alicia, García-Álvarez Lara, Pajarón Marcos, Ribas María Angels, Blanes-Hernández Rosa, López-Montesinos Inmaculada, López-Cortés Luis E, Vidal Bárbara, Fernández-Pittol Mariana, Navarro Dolores, Moreno Asunción, Sala Coral, Ambrosioni Juan, Miró José M
Infectious Diseases Department, Hospital Clinic-IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
CIBERINFEC, Instituto de Salud Carlos III, Madrid, Spain.
Infect Dis Ther. 2025 Mar;14(3):643-655. doi: 10.1007/s40121-025-01110-9. Epub 2025 Mar 1.
The POET trial demonstrated that moving from intravenous to oral antibiotics in stable patients with left-sided infective endocarditis (IE) was noninferior to fully parenteral treatment. However, it did not compare outpatient strategies.
The OraPAT-IE GAMES trial is a noninferiority, multicenter, randomized, open-label study aimed to compare partial oral versus outpatient parenteral antibiotic therapy (OPAT) for consolidation of antibiotic treatment in left-sided IE. A total of 342 stable patients with IE caused by selected micro-organisms will eventually be included. After a minimum of 10 days of parenteral treatment, stable patients are randomized to oral therapy or OPAT. The primary end-point is a composite of all-cause mortality, unplanned cardiac surgery, relapse of positive blood cultures and/or unplanned hospital admission. Patients are followed-up for 6 months after completing antibiotic therapy.
This trial seeks to demonstrate the equivalent efficacy of the two outpatient strategies currently available for stable patients with IE in the consolidation phase of antibiotic treatment.
In a global context of limited healthcare resources and a sustained increase in elderly and frail patients, it is of great importance to demonstrate the effectiveness and safety of outpatient management strategies that could reduce the duration of conventional hospitalizations with their potential complications and inherent costs.
EudraCT: 2020-001024-34.
gov identifier: NCT05398679.
POET试验表明,对于稳定的左侧感染性心内膜炎(IE)患者,从静脉抗生素治疗转为口服抗生素治疗并不劣于全胃肠外治疗。然而,该试验未比较门诊治疗策略。
OraPAT-IE GAMES试验是一项非劣效性、多中心、随机、开放标签研究,旨在比较部分口服与门诊胃肠外抗生素治疗(OPAT)在左侧IE抗生素治疗巩固阶段的效果。最终将纳入总共342例由特定微生物引起的稳定IE患者。在至少10天的胃肠外治疗后,稳定的患者被随机分配接受口服治疗或OPAT。主要终点是全因死亡率、非计划性心脏手术、血培养阳性复发和/或非计划性住院的综合指标。患者在完成抗生素治疗后随访6个月。
本试验旨在证明目前可用于稳定IE患者抗生素治疗巩固阶段的两种门诊治疗策略具有等效疗效。
在全球医疗资源有限以及老年和体弱患者持续增加的背景下,证明门诊管理策略的有效性和安全性非常重要,这些策略可以减少传统住院时间及其潜在并发症和固有成本。
EudraCT:2020-001024-34。
gov标识符:NCT05398679。